» Articles » PMID: 36411581

Differentiation of Clear Cell and Non-clear-cell Renal Cell Carcinoma Through CT-based Radiomics Models and Nomogram

Overview
Specialty Radiology
Date 2022 Nov 22
PMID 36411581
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: The aim of the study was to investigate the feasibility of discriminating between clear-cell renal cell carcinoma (ccRCC) and non-clear-cell renal cell carcinoma (non-ccRCC) via radiomics models and nomogram.

Methods: The retrospective study included 147 patients (ccRCC=100, non-ccRCC=47) who underwent enhanced CT before surgery. CT images of the corticomedullary phase (CMP) were collected and features from the images were extracted. The data were randomly grouped into training and validation sets according to 7:3, and then the training set was normalized to extract the normalization rule for the training set, and then the rule was applied to the validation set. First, the T-test, T'-test or Wilcoxon rank-sum test were executed in the training set data to keep the statistically different parameters, and then the optimal features were picked based on the least absolute shrinkage and selection operator (LASSO) algorithm. Five machine learning (ML) models were trained to differentiate ccRCC from noccRCC, rad+cli nomogram was constructed based on clinical factors and radscore (radiomics score), and the performance of the classifier was mainly measured by area under the curve (AUC), accuracy, sensitivity, specificity, and F1. Finally, the ROC curves and radar plots were plotted according to the five performance parameters.

Results: 1130 radiomics features were extracted, there were 736 radiomics features with statistical differences were obtained, and 4 features were finally selected after the LASSO algorithm. In the validation set of this study, three of the five ML models (logistic regression, random forest and support vector machine) had excellent performance (AUC 0.9-1.0) and two models (adaptive boosting and decision tree) had good performance (AUC 0.7-0.9), all with accuracy ≥ 0.800. The rad+cli nomogram performance was found excellent in both the training set (AUC = 0.982,0.963-1.000, accuracy=0.941) and the validation set (AUC = 0.949,0.885-1.000, accuracy=0.911). The random forest model with perfect performance (AUC = 1, accuracy=1) was found superior compared to the model performance in the training set. The rad+cli nomogram model prevailed in the comparison of the model's performance in the validation set.

Conclusion: The ML models and nomogram can be used to identify the relatively common pathological subtypes in clinic and provide some reference for clinicians.

Citing Articles

Imaging in Renal Cell Carcinoma Detection.

Woon D, Qin S, Al-Khanaty A, Perera M, Lawrentschuk N Diagnostics (Basel). 2024; 14(18).

PMID: 39335784 PMC: 11431198. DOI: 10.3390/diagnostics14182105.


Clear cell and non-clear cell renal cell carcinoma in young adults: clinicopathological features, survival outcomes and prognostic factors.

Xue Z, Tang S, Ou J, Fang Y, Qiu M, Hong K World J Urol. 2024; 42(1):364.

PMID: 38819448 DOI: 10.1007/s00345-024-05028-8.

References
1.
Canino C, Perrone L, Bosco E, Saltalamacchia G, Mosca A, Rizzo M . Targeting angiogenesis in metastatic renal cell carcinoma. Expert Rev Anticancer Ther. 2019; 19(3):245-257. DOI: 10.1080/14737140.2019.1574574. View

2.
Cheville J, Lohse C, Zincke H, Weaver A, Blute M . Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am J Surg Pathol. 2003; 27(5):612-24. DOI: 10.1097/00000478-200305000-00005. View

3.
Hsieh J, Purdue M, Signoretti S, Swanton C, Albiges L, Schmidinger M . Renal cell carcinoma. Nat Rev Dis Primers. 2017; 3:17009. PMC: 5936048. DOI: 10.1038/nrdp.2017.9. View

4.
Ljungberg B, Albiges L, Abu-Ghanem Y, Bedke J, Capitanio U, Dabestani S . European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update. Eur Urol. 2022; 82(4):399-410. DOI: 10.1016/j.eururo.2022.03.006. View

5.
Van der Kwast T, Perez-Ordonez B . Renal oncocytoma, yet another tumour that does not fit in the dualistic benign/malignant paradigm?. J Clin Pathol. 2007; 60(6):585-6. PMC: 1955085. DOI: 10.1136/jcp.2006.044438. View